


RESEARCH ARTICLE

Open Access



# Aerobic and resistance exercise improves physical fitness, bone health, and quality of life in overweight and obese breast cancer survivors: a randomized controlled trial

Christina M Dieli-Conwright<sup>1,5\*</sup> , Kerry S Courneya<sup>2</sup>, Wendy Demark-Wahnefried<sup>3</sup>, Nathalie Sami<sup>1</sup>, Kyuwan Lee<sup>1</sup>, Frank C Sweeney<sup>1</sup>, Christina Stewart<sup>1</sup>, Thomas A Buchanan<sup>4</sup>, Darcy Spicer<sup>5</sup>, Debu Tripathy<sup>6</sup>, Leslie Bernstein<sup>7</sup> and Joanne E Mortimer<sup>8</sup>

## Abstract

**Background:** Exercise is an effective strategy to improve quality of life and physical fitness in breast cancer survivors; however, few studies have focused on the early survivorship period, minorities, physically inactive and obese women, or tested a combined exercise program and measured bone health. Here, we report the effects of a 16-week aerobic and resistance exercise intervention on patient-reported outcomes, physical fitness, and bone health in ethnically diverse, physically inactive, overweight or obese breast cancer survivors.

**Methods:** One hundred breast cancer survivors within 6 months of completing adjuvant treatment were assessed at baseline, post-intervention, and 3-month follow-up (exercise group only) for physical fitness, bone mineral density, serum concentrations of bone biomarkers, and quality of life. The exercise intervention consisted of moderate-vigorous (65–85% heart rate maximum) aerobic and resistance exercise thrice weekly for 16 weeks. Differences in mean changes for outcomes were evaluated using mixed-model repeated measure analysis.

**Results:** At post-intervention, the exercise group was superior to usual care for quality of life (between group difference: 14.7, 95% CI: 18.2, 9.7;  $p < 0.001$ ), fatigue ( $p < 0.001$ ), depression ( $p < 0.001$ ), estimated  $VO_{2max}$  ( $p < 0.001$ ), muscular strength ( $p < 0.001$ ), osteocalcin ( $p = 0.01$ ), and BSAP ( $p = 0.001$ ). At 3-month follow-up, all patient-reported outcomes and physical fitness variables remained significantly improved compared to baseline in the exercise group ( $p < 0.01$ ).

**Conclusions:** A 16-week combined aerobic and resistance exercise program designed to address metabolic syndrome in ethnically-diverse overweight or obese breast cancer survivors also significantly improved quality of life and physical fitness. Our findings further support the inclusion of supervised clinical exercise programs into breast cancer treatment and care.

**Trial registration:** This trial is registered on ClinicalTrials.gov: [NCT01140282](https://clinicaltrials.gov/ct2/show/study/NCT01140282) as of June 9, 2010.

**Keywords:** Exercise, quality of life, physical fitness, bone health, breast cancer

\* Correspondence: [cdieli@usc.edu](mailto:cdieli@usc.edu)

<sup>1</sup>Division of Biokinesiology and Physical Therapy, University of Southern California (USC), 1540 E. Alcazar St., CHP 155, Los Angeles, CA 90089, USA

<sup>5</sup>Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA

Full list of author information is available at the end of the article



© The Author(s). 2018 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

## Background

Breast cancer survivors are at elevated risk for the development of comorbid conditions such as sarcopenia, osteoporosis, and cardiovascular disease [1] which contribute to declines in quality of life, cardiorespiratory fitness, muscular strength, and bone health. These negative health concerns are partly induced by cancer-related treatments (e.g., chemotherapy, radiation, endocrine therapy) and are exacerbated by obesity and a physically inactive lifestyle. Exercise is an effective non-pharmacologic strategy to mitigate cancer-related treatment side effects and improve quality of life, cardiorespiratory fitness, and muscular strength in breast cancer survivors [2]; however, few studies have focused on the early survivorship period ( $\leq 6$  months post-treatment), minorities, physically inactive and obese women, or tested a combined exercise program and measured bone health.

The overall purpose of this trial was to compare a 16-week supervised moderate-vigorous intensity aerobic and resistance exercise intervention to usual care in physically inactive, overweight and obese breast cancer survivors. We previously reported that the exercise intervention led to significant improvements in metabolic syndrome, sarcopenic obesity, and circulating biomarkers that were maintained at 3-month follow-up [3]. Here, we report the secondary outcomes of physical fitness, bone health, and quality of life. We hypothesized that a combined exercise intervention performed within 6 months of cancer treatment completion would improve patient-reported outcomes, physical fitness, and bone health in ethnically-diverse, physically inactive, overweight/obese breast cancer survivors compared to usual care.

## Methods

### Participants/Consent

Eligible participants were  $< 6$  months post-treatment for chemo- or radiation-therapy for stage 0-III breast cancer and were non-smokers, physically inactive ( $< 60$  min of structured exercise/week), with BMI  $\geq 25.0$  kg/m<sup>2</sup> (or body fat  $> 30\%$ ) and waist circumference  $> 88$  cm. Participants were verbally screened for eligibility by phone or in person at time of consent. Treatment history and diagnosis were confirmed by medical record abstraction. Body composition measure were obtained at time of screening per testing methods described below (Covariate Measures).

Recruitment occurred between August 1, 2012 and December 31, 2016 from the USC Norris Comprehensive Cancer Center and Los Angeles County Hospital. The protocol and informed consent were IRB-approved (HS-12-00141) and registered (ClinicalTrials.gov:NCT01140282). A signed informed consent was obtained from each participant.

Participants were randomized to exercise or usual care following the completion of baseline testing using concealed randomization lists.

### Experimental Design

This randomized controlled trial compared a progressive combined (aerobic and resistance) exercise intervention versus usual care on baseline to 4-month changes in physical fitness, bone health, and patient-reported outcomes. Detailed methods [4], and primary outcomes related to metabolic syndrome were published previously. Endpoints were assessed at baseline, post-intervention (month 4), and 3-month follow-up (exercise group only). To enhance participation, usual care participants were offered the exercise program following the study period.

### Cardiorespiratory Fitness

A single-stage submaximal treadmill test was used to estimate maximal oxygen uptake,  $VO_{2max}$  [5]. Participants first performed a 4-min warm up by walking on a treadmill (Desmo Woodway, Waukesha, WI) at a speed (2.0, 3.0, 4.0, or 4.5 mph) that increased their heart rate between 50 and 70% heart rate maximum. This was followed by the 4-min test at the same speed with a 5% grade; heart rate was measured during the final 30 s of the test. Using heart rate, speed, age and gender, estimated maximal oxygen uptake was predicted using the test-specific regression formula [5].

### Muscular Strength

Estimated maximal voluntary strength (1-RM) was assessed for the chest press, latissimus pulldown, knee extension, and knee flexion using the 10-repetition maximum (10-RM) method (Tuff Stuff, Pomona, CA). [6] Participants completed a warm-up load of  $\sim 5$ –8-RM before attempting 10-RM. A 2-min rest period was given between attempts; 3–5 attempts were performed.

### Dual Energy X-Ray Absorptiometry (DXA)

Dual hip and lumbar DXA scans were used to assess bone mineral density (BMD; Lunar GE iDXA, Fairfield, Connecticut).

### Blood Collection and Analysis

Fasting ( $\geq 12$  h) blood was obtained by trained phlebotomists. Serum was stored at  $-80^{\circ}$  until batch analysis at study completion. Biomarkers of bone turnover were analyzed and included bone-specific alkaline phosphatase (BSAP) and osteocalcin as markers of bone formation, C-telopeptide of type 1 collagen (CTX), N-telopeptides of type 1 collagen (NTX) as markers of bone resorption, and receptor activator factor-kappa B (RANK) and receptor activator factor-kappa B ligand (RANKL) as

markers of bone remodeling. In addition, we quantified calcium and 25-hydroxyvitamin D.

Osteocalcin (Meso Scale Discovery, Rockville MD, Catalog #K151HHC-1), BSAP (Ostase Assay Catalog #37300, Beckman Coulter, Ontario, Canada), CTX (Immunodiagnosics, Gaithersburg, MD, Catalog #AC-02F1), NTX (MyBioSource, San Diego, CA, Catalog #MBS705111), RANK (MyBioSource, San Diego, CA, Catalog #MBS9308775), and RANKL (MyBioSource, San Diego, CA, Catalog #MBS2533374) were analyzed by enzyme-linked immunoabsorbent assays. 25-hydroxyvitamin D was detected by high-performance liquid chromatography (Dionex Corporation, Sunnyvale, CA). Calcium was detected using an automated colorimetric technique including an ion-specific assay (abcam, Cambridge, MA Catalog #ab102505) and a colorimetric microplate reader (BioTek, Winooski, VT). Duplicate testing was performed with coefficients of variation for all samples < 10%.

#### Patient-reported Outcomes

Quality of Life was assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-B) and the Short Form-36 Health Survey (SF-36). The Brief Fatigue Inventory (BFI) was used to assess fatigue, where a lower score indicates less fatigue [7]. Risk for depression and depressive symptoms were assessed using the 20-item Center for Epidemiologic Studies-Depression Scale (CES-D) [8].

#### Covariate Measures

Weight was measured to the nearest 0.1 kg on an electronic scale with the patient wearing a hospital gown and no shoes and height was measured to the nearest 0.5 cm with a fixed stadiometer in order to calculate BMI. Waist circumference was measured at the mid-point between the lower margin of the last palpable rib and the iliac crest. Physical activity history was assessed at baseline using an interviewer-administered, validated questionnaire to assess historical, past-year, and past-week physical activity [9]. Three-day dietary records (2 weekdays and 1 weekend day) were completed at baseline, post-intervention, and 3-month follow-up (exercise group only) within 1-week of each assessment and analyzed using Nutritionist Pro™ (Woodinville, WA). Participants completed the Charlson Comorbidity questionnaire [10]. Cancer-related information (i.e., time since treatment completion, time since diagnosis, disease stage, hormone-receptor status, endocrine therapy, and surgery) was abstracted from medical records.

#### Exercise Intervention

The exercise program aligned with ACS/ACSM exercise guidelines for cancer survivors (150 min of aerobic

exercise and 2–3 days of resistance exercise training/week) [11]. Participants received 3 supervised one-on-one exercise sessions/week. Days 1 and 3 consisted of aerobic and resistance exercise of ~80 min and Day 2 included ~50 min of aerobic exercise. All sessions were led by a certified ACS/ACSM Cancer Exercise Trainer. Participants wore a Polar® heart monitor (Lake Success, NY) during each exercise session. Each session began with a 5-min aerobic exercise warm-up at 40–50% estimated  $\text{VO}_2\text{max}$ . Sequenced resistance exercise followed in circuit training fashion with no rest periods between exercises: Leg Press  $\Leftrightarrow$  Chest Press  $\Rightarrow$  Lunges  $\Leftrightarrow$  Seated Row  $\Rightarrow$  Leg Extensions  $\Leftrightarrow$  Triceps Extensions  $\Rightarrow$  Leg Flexion  $\Leftrightarrow$  Biceps Curl; where  $\Leftrightarrow$  indicates the two exercises that alternated until all sets were completed, then the following pair of exercises was performed. Initial resistance was set at 80% of the estimated 1-RM for lower body exercises and 60% estimated 1-RM for upper body exercises. When the participant was able to complete three sets of 10 repetitions at the set weight in two consecutive sessions then the weight is increased by 10%. Repetitions increased from 10 (week 4) to 12 (week 8) to 15 (week 12) every 4 weeks to safely build muscular endurance. Compression garments were required during the exercise sessions for all participants who held prescriptions.

Resistance exercises were followed by self-selected aerobic exercise: treadmill walking/running; rowing machine; stationary bicycle. Heart rate (HR) was monitored throughout the aerobic sessions to maintain a HR at 65–80% of maximum HR. Target HR was increased every 4 weeks to safely build cardiorespiratory endurance and to maintain the prescribed intensity as participants improved their cardiorespiratory fitness. Duration of the aerobic sessions was increased from 30 min (week 1) to 50 min (week 16) as cardiorespiratory fitness increased to meet the exercise guidelines for cancer survivors. Participants ended each session with a 5-min cool down at 40–50% estimated  $\text{VO}_2\text{max}$ . The trainers documented attendance and minutes of exercise per session.

#### Follow-up period (exercise group only)

A 12-week follow-up was instituted in the exercise group to assess intervention durability. During the 12-week period, participants were encouraged to exercise on their own without study team supervision. Participants were asked to maintain weekly physical activity logs and wear an accelerometer on a daily basis during this period; they repeated outcome measure testing upon completion of the 12-week period. Sustainability was assessed at 28-week follow-up in this group by 7-day accelerometer monitoring (Model GT3X Actigraph, Fort Walton Beach, FL). Participants were asked to wear the accelerometer during waking hours for 7 consecutive

days, perform their normal or usual activity, and remove the device while bathing, showering, or swimming. Participants received verbal and written instructions and a wear time log to encourage adherence. Devices were returned at time of follow-up testing. Accelerometer data was used to estimate minutes and intensity of physical activity performed according to the manufacturer's directions.

### Statistical Analyses

As this is a secondary analysis of the parent trial which focused on metabolic syndrome, the sample size was based on projected changes in insulin [12]. Enrollment of 100 women provided 80% statistical power ( $\alpha = 0.05$ ) to detect a 2.6  $\mu\text{U/ml}$  (SD = 4.0  $\mu\text{U/ml}$ ) difference in mean insulin levels assuming 20% drop-out using a two-group t-test.

Within-group differences in mean changes for individual outcomes measured at post-intervention and 3-month follow-up (exercise group only) were evaluated using general linear models repeated-measures ANOVAs. Between-group differences in mean changes for individual outcomes measured at post-intervention were evaluated using mixed-model repeated measure analysis. A priori covariates included type of treatment (chemotherapy, radiation, or both), surgery type, time on hormonal therapy, comorbidities, and BMI were explored in models due to their possible associations with outcomes, but none modified results. Five women using bisphosphonates were excluded when analyzing BMD and other bone biomarkers.

Post-hoc analyses included stratification by menopausal status at time of diagnosis. (women were classified as postmenopausal if amenorrheic over the previous 12 months). Analyses were performed using SAS (Version 9.4, Cary, NC).

### Results

The study CONSORT diagram is reported elsewhere. Briefly, we assessed 418 women for eligibility of which 100 were randomized to the exercise or usual care group. Four participants in the exercise group and five participants in the usual care group did not complete the study. Baseline characteristics also are reported elsewhere and were similar across the 2 groups. On average, women were  $53.5 \pm 10.4$  (SD) years old, postmenopausal (60%), Hispanic white (55%) or non-Hispanic white (26%),  $6.2 \pm 2.1$  months from diagnosis, with a BMI =  $33.5 \pm 5.5$   $\text{kg/m}^2$ . Women were diagnosed primarily with stage I (40%) or II (38%) breast cancer and largely treated with both chemo- and radiation- therapy (76%). The weekly average of moderate-to-vigorous physical activity at baseline was  $9.6 \pm 6.8$  min.

Intervention adherence and adverse events are reported elsewhere. High session attendance of 96% (overall average 46 of 48 sessions) was attained by the exercise group. Adherence with aerobic exercise, and with intensity and volume of resistance exercises was 95%. No adverse events were reported over the duration of the study.

### Physical Fitness

Physical fitness outcomes are displayed in Table 1. Estimated  $\text{VO}_{2\text{max}}$ , an indicator of cardiorespiratory fitness, significantly increased in the exercise group as compared to baseline and the usual care group ( $p\text{-value} < 0.001$ ). Resting heart rate significantly decreased in the exercise group as compared to baseline and the usual care group ( $p\text{-value} < 0.001$ ). Muscle strength, assessed as estimated 1-RM, significantly increased across all four exercises (leg extension, leg flexion, latissimus pulldown, chest press) in the exercise group as compared to baseline and the usual care group ( $p\text{-values} < 0.001$ ). At follow-up, all physical fitness measures remained significantly improved in the exercise group compared to baseline ( $p\text{-values} < 0.001$ ). The usual care group did not experience changes in any measure of physical fitness ( $p\text{-values} > 0.05$ ).

### Bone Health

Table 2 shows baseline, post-intervention, and 3-month follow-up changes in BMD and bone biomarkers by group. Post-intervention, BMD (whole body, lumbar spine, total hip, trochanter, and femoral neck) did not significantly change in the exercise or usual care groups ( $p > 0.10$ ). Calcium and 25-hydroxyvitamin D levels increased ( $p = 0.09$ ) in the exercise group however this did not reach significance. Osteocalcin and BSAP, biomarkers of bone formation, increased in the exercise as compared to baseline ( $p = 0.04$ ,  $0.05$ , respectively) and the usual care group ( $p = 0.01$ ,  $0.07$ , respectively) however, significance was only reached for osteocalcin. Post-intervention, CTX and NTX, biomarkers of bone resorption, and RANK and RANKL, biomarkers of bone remodeling, did not significantly change in the exercise or usual care groups ( $p > 0.05$ ). Stratification by menopausal status did not alter these results.

### Patient-Reported Outcomes

Tables 3 and 4 display patient-reported outcomes. Post-intervention, FACT-B scores (Table 3) were significantly improved in exercise vs. usual care (between group difference: 14.7, 95% CI: 18.2, 9.7;  $p < 0.001$ ). FACT-General, trial outcome index, and all subscales were significantly improved in the exercise group when compared to baseline ( $p \leq 0.01$ ) and the usual care group ( $p < 0.001$ ). All SF-36 subscores (Table 4) significantly



**Table 1** Comparison of physical fitness between exercise and usual care groups

	Baseline	Post-intervention		3-month follow-up		Between-group difference post-intervention	
	Mean (SD)	Mean (SD)	P value <sup>a</sup>	Mean (SD)	P value <sup>b</sup>	Mean (95% CI)	P value <sup>c</sup>
Estimated VO <sub>2max</sub> (mL/kg/min)							
Exercise	23.3 (6.1)	35.1 (8.0)	< 0.001	32.1 (8.2)	< 0.001	11.8 (25.2 to 16.7)	< 0.001
Usual care	22.7 (6.4)	19.3 (8.5)	0.14	–	–		
Resting heart rate (bpm)							
Exercise	87.9 (8.0)	77.5 (8.5)	< 0.001	76.9 (8.9)	< 0.001	–15.4 (–18.1 to –11.7)	< 0.001
Usual care	87.7 (7.7)	88.1 (7.8)	0.67	–	–		
Leg extension (kgs)							
Exercise	45.4 (10.6)	75.7 (10.8)	< 0.001	77.4 (11.5)	< 0.001	30.4 (35.9 to 27.8)	< 0.001
Usual care	44.9 (9.1)	42.9 (9.0)	0.15	–	–		
Leg flexion (kgs)							
Exercise	39.5 (9.6)	63.6 (11.2)	< 0.001	62.4 (12.1)	< 0.001	24.0 (27.2 to 21.6)	< 0.001
Usual care	40.8 (10.1)	39.7 (10.6)	0.23	–	–		
Latissimus pulldown (kgs)							
Exercise	30.6 (4.7)	39.0 (6.1)	< 0.001	38.5 (6.5)	< 0.001	9.6 (11.7 to 6.1)	< 0.001
Usual care	30.3 (4.0)	29.6 (4.4)	0.27	–	–		
Chest press (kgs)							
Exercise	9.1 (2.3)	20.7 (4.5)	< 0.001	19.5 (4.0)	< 0.001	11.6 (15.9 to 7.7)	< 0.001
Usual care	9.2 (2.5)	8.7 (2.4)	0.40	–	–		

**Abbreviations:** SD standard deviation, CI confidence interval, kgs kilograms

<sup>a</sup>P value for repeated measures ANOVA comparing changes in the exercise group from baseline to post-intervention, and in the usual care group from baseline to post-intervention

<sup>b</sup>P value for repeated measures ANOVA comparing changes in the exercise group from baseline to 3-month follow-up

<sup>c</sup>P value for mixed model analysis comparing changes between the exercise and usual care group from baseline to post-intervention

improved in the exercise group when compared to baseline and the usual care group ( $p \leq 0.001$ ). Fatigue and depression (Table 4) significantly reduced in the exercise group as compared to baseline ( $p \leq 0.01$ ) and the usual care group ( $p < 0.001$ ). At follow-up, all patient-reported outcome measures remained significantly improved in the exercise group compared to baseline ( $p < 0.001$ ).

## Discussion

A supervised 16-week aerobic and resistance exercise intervention designed to improve metabolic syndrome also led to significant improvements in quality of life, depression, fatigue, and physical fitness that were maintained at 3-month follow-up among ethnically-diverse, physically inactive, and overweight/obese breast cancer survivors. While the intervention did not alter bone density, osteocalcin and BSAP showed significant improvements. This is the first study to our knowledge to significantly improve these outcomes with a structured combined exercise intervention in an ethnically-diverse sample of overweight or obese breast cancer survivors soon after treatment. These results are impactful given that quality of life, fatigue, and physical deconditioning are some of the most common and persevering symptoms reported by breast cancer survivors [13, 14]. This

work supports the ACS/ACSM exercise guidelines for cancer survivors and demonstrates successful integration of these guidelines for women from different ethnic backgrounds.

Remarkable improvements in patient-reported outcomes were observed for quality of life, fatigue, and depressive symptoms. While our results align with those reported in the literature [15, 16], the exercise-induced reductions in fatigue (effect size  $d = 0.91$ ) and depressive symptomatology (effect size  $d = 0.97$ ) are unparalleled with substantially larger effect sizes than the 0.30 and 0.38 reported from recent meta-analyses examining exercise and fatigue [16] and depressive symptoms [17], respectively, in cancer survivors. The marked reduction in these two domains may be due to the inclusion of women within a short period (6 months) of concluding cancer-related treatment, the physically inactive and obese nature of the participants upon enrollment, and the ethnically diverse sample. Further, it is plausible that the combination of aerobic and resistance exercise, in a supervised manner, resulted in greater benefits on patient-reported outcomes than only one mode of exercise. Previous studies have integrated a supervised combined exercise intervention with significant improvements in quality of life [18–23], fatigue [20], and

**Table 2** Comparison of bone health between exercise and usual care groups

	Baseline	Post-intervention		3-month follow-up		Between-group difference post-intervention	
	Mean (SD)	Mean (SD)	P value <sup>a</sup>	Mean (SD)	P value <sup>b</sup>	Mean (95% CI)	P value <sup>c</sup>
Calcium (mg/dL)							
Exercise	10.3 (2.6)	13.7 (1.9)	0.09	13.4 (1.7)	0.10	3.4 (5.0 to 1.6)	0.10
Usual care	10.5 (2.5)	9.9 (2.6)	0.67	–	–		
25(OH)D (ng/dL)							
Exercise	21.7 (4.4)	27.8 (6.7)	0.09	27.4 (6.5)	0.09	6.1 (9.8 to 4.3)	0.10
Usual care	21.5 (4.1)	20.9 (4.0)	0.57	–	–		
Osteocalcin (ng/mL)							
Exercise	12.1 (3.1)	15.0 (4.1)	0.01	14.7 (3.5)	0.01	3.1 (5.6 to 1.5)	0.01
Usual care	12.3 (3.4)	12.0 (3.0)	0.61	–	–		
BSAP (ng/mL)							
Exercise	16.1 (4.6)	18.0 (5.0)	0.01	17.7 (4.6)	0.01	1.9 (2.4 to 0.55)	0.001
Usual care	16.2 (4.3)	15.9 (4.2)	0.55	–	–		
CTX (ng/mL)							
Exercise	0.48 (0.1)	0.44 (0.2)	0.07	0.44 (0.2)	0.07	–0.04 (–0.10 to –0.06)	0.10
Usual care	0.47 (0.1)	0.48 (0.2)	0.74	–	–		
NTX (nM BCE/L)							
Exercise	18.6 (3.1)	17.7 (2.8)	0.10	17.8 (2.7)	0.11	–0.90 (–1.1 to –0.6)	0.12
Usual care	18.4 (2.7)	18.3 (2.5)	0.67	–	–		
RANK (pg/mL)							
Exercise	27.4 (6.8)	26.7 (6.4)	0.14	26.6 (6.1)	0.14	–0.70 (–0.9 to –0.4)	0.20
Usual care	26.9 (6.6)	26.4 (6.5)	0.34	–	–		
RANKL (pmol/L)							
Exercise	142.5 (18.9)	146.1 (16.1)	0.09	145.7 (16.2)	0.09	3.6 (5.1 to 1.2)	0.14
Usual care	139.8 (18.1)	148.8 (18.9)	0.47	–	–		
Whole body BMD (g/cm <sup>2</sup> )							
Exercise	1.22 (0.1)	1.27 (0.1)	0.15	1.26 (0.1)	0.16	0.05 (0.04 to 0.02)	0.15
Usual care	1.20 (0.1)	1.19 (0.1)	0.29	–	–		
Lumbar spine BMD (g/cm <sup>2</sup> )							
Exercise	1.16 (0.09)	1.20 (0.09)	0.09	1.20 (0.1)	0.09	0.04 (0.03 to 0.01)	0.10
Usual care	1.15 (0.09)	1.14 (0.09)	0.57	–	–		
Total hip BMD (g/cm <sup>2</sup> )							
Exercise	0.91 (0.09)	0.94 (0.09)	0.17	0.94 (0.09)	0.17	0.03 (0.03 to 0.00)	0.18
Usual care	0.90 (0.09)	0.89 (0.08)	0.23	–	–		
Trochanter BMD (g/cm <sup>2</sup> )							
Exercise	0.72 (0.07)	0.74 (0.07)	0.18	0.74 (0.07)	0.20	0.02 (0.03 to 0.00)	0.22
Usual care	0.71 (0.06)	0.70 (0.06)	0.43	–	–		
Femoral neck BMD (g/cm <sup>2</sup> )							
Exercise	0.88 (0.1)	0.90 (0.1)	0.21	0.88 (0.7)	0.24	0.02 (0.03 to 0.00)	0.21
Usual care	0.87 (0.1)	0.86 (0.1)	0.23	–	–		

**Abbreviations:** SD standard deviation, CI confidence interval, BMD bone mineral density, RANK receptor activator factor-kappa B, RANKL receptor activator factor-kappa B ligand

<sup>a</sup>P value for repeated measures ANOVA comparing changes in the exercise group from baseline to post-intervention, and in the usual care group from baseline to post-intervention

<sup>b</sup>P value for repeated measures ANOVA comparing changes in the exercise group from baseline to 3-month follow-up

<sup>c</sup>P value for mixed model analysis comparing changes between the exercise and usual care group from baseline to post-intervention

**Table 3** Comparison of breast cancer-specific quality of life between exercise and usual care groups

	Baseline	Post-intervention		3-month follow-up		Between-group difference post-intervention	
	Mean (SD)	Mean (SD)	P value <sup>a</sup>	Mean (SD)	P value <sup>b</sup>	Mean (95% CI)	P value <sup>c</sup>
Physical well-being							
Exercise	19.2 (3.1)	23.2 (3.0)	< 0.001	23.1 (3.2)	< 0.001	3.9 (7.2 to 1.7)	0.003
Usual care	19.1 (3.4)	19.1 (3.5)	0.74	–	–		
Social well-being							
Exercise	19.7 (3.0)	23.0 (3.2)	< 0.001	23.0 (3.0)	< 0.001	3.3 (6.9 to 1.1)	0.005
Usual care	19.6 (3.1)	19.5 (3.0)	0.81	–	–		
Emotional well-being							
Exercise	18.4 (2.6)	20.1 (3.1)	0.01	20.1 (3.5)	0.01	1.7 (3.4 to 0.8)	0.01
Usual care	18.3 (2.5)	18.2 (2.7)	0.75	–	–		
Functional well-being							
Exercise	19.9 (3.4)	22.0 (3.2)	0.01	21.9 (3.1)	0.01	2.0 (4.2 to 0.6)	0.01
Usual care	20.0 (3.6)	19.9 (3.3)	0.83	–	–		
Additional concerns							
Exercise	21.1 (4.7)	24.7 (4.1)	0.002	24.0 (4.5)	0.001	3.6 (7.7 to 2.0)	0.002
Usual care	21.7 (4.4)	19.6 (10.4)	0.43	–	–		
FACT-General							
Exercise	77.2 (9.0)	88.3 (9.9)	< 0.001	88.1 (9.2)	< 0.001	11.1 (16.4 to 7.7)	< 0.001
Usual care	77.0 (9.1)	76.7 (9.0)	0.54	–	–		
FACT-Breast							
Exercise	98.3 (14.1)	113.0 (13.0)	< 0.001	112.1 (13.2)	< 0.001	14.7 (18.2 to 9.7)	< 0.001
Usual care	98.7 (14.4)	96.3 (14.5)	0.44	–	–		
Trial outcome index							
Exercise	60.2 (7.3)	69.9 (7.5)	< 0.001	69.0 (7.7)	< 0.001	8.8 (15.3 to 4.3)	< 0.001
Usual care	60.8 (7.5)	58.6 (7.4)	0.64	–	–		

**Abbreviations:** SD standard deviation, CI confidence interval, FACT Functional Assessment of Cancer Therapy

<sup>a</sup>P value for repeated measures ANOVA comparing changes in the exercise group from baseline to post-intervention, and in the usual care group from baseline to post-intervention

<sup>b</sup>P value for repeated measures ANOVA comparing changes in the exercise group from baseline to 3-month follow-up

<sup>c</sup>P value for mixed model analysis comparing changes between the exercise and usual care group from baseline to post-intervention

depression [18] yet achieved a magnitude of improvement lower than our results. Differences in exercise duration, intensity, and frequency may underlie the various magnitudes of change across outcomes.

Physical function, described as the ability of an individual to perform common daily activities has been shown to predict survival and mortality in breast cancer survivors [24, 25], and thus is gaining support as a relevant prognostic indicator among cancer survivors. One determinant of physical function is one's level of physical fitness, thereby improving physical fitness as a means to improve physical function is of high importance. We found notable improvements in estimated  $\text{VO}_{2\text{max}}$  (52%) and muscular strength (> 30%) following exercise. For example, estimated 1-RM for chest press increased by 133%. Previous studies utilizing a supervised combined exercise intervention have produced significant improvements in physical fitness [18–23, 26] yet to a lesser

degree than our results. Various exercise fitness testing methodologies (i.e., six-minute walk test, 12-min walk test, Aerobic Power Index cycle test, modified Bruce treadmill test) were used across studies, challenging the interpretation of results and between-study comparisons. Moreover, we used indirect assessment of  $\text{VO}_{2\text{max}}$  that involved the use of a regressions formula which may have influenced our results.

Our large exercise-induced effects on physical fitness may be due to the high rate of physically inactive behavior at baseline, and subsequent low physical fitness levels at baseline, the early survivorship phase, high adherence, a supervised environment, and inclusion of both aerobic and resistance exercise. In particular, most (95%) of our Hispanic white participants had no history of physical activity and therefore may have experienced greater gains in the outcomes from the intervention. The large increase in maximal strength for the chest press may be

**Table 4** Comparison of health status, fatigue, and depression between exercise and usual care groups

	Baseline	Post-intervention		3-month follow-up		Between-group difference post-intervention	
	Mean (SD)	Mean (SD)	P value <sup>a</sup>	Mean (SD)	P value <sup>b</sup>	Mean (95% CI)	P value <sup>c</sup>
SF-36 SUBSCORES							
Physical functioning							
Exercise	65.3 (9.4)	74.1 (9.5)	0.001	73.9 (8.9)	0.001	9.2 (12.3 to 7.7)	0.001
Usual care	65.0 (9.7)	64.1 (9.8)	0.77	–	–		
Role-physical							
Exercise	68.4 (8.6)	75.7 (9.1)	0.002	74.4 (9.5)	0.003	7.3 (10.9 to 4.8)	0.001
Usual care	67.9 (9.1)	66.9 (8.7)	0.55	–	–		
Bodily pain							
Exercise	50.5 (9.6)	63.3 (11.2)	0.001	62.1 (12.1)	0.001	13.2 (17.2 to 9.6)	0.001
Usual care	50.8 (10.1)	49.7 (10.3)	0.23	–	–		
General health							
Exercise	60.1 (11.7)	67.2 (11.1)	0.002	67.0 (10.5)	0.001	7.1 (11.7 to 4.0)	0.002
Usual care	59.7 (11.0)	57.6 (10.4)	0.43	–	–		
Mental health							
Exercise	69.1 (12.3)	77.7 (12.5)	0.003	75.5 (11.0)	0.001	8.6 (12.9 to 5.7)	0.001
Usual care	69.7 (12.5)	68.7 (13.0)	0.60	–	–		
Role-emotional							
Exercise	70.1 (11.3)	83.7 (12.5)	0.001	82.0 (12.0)	0.001	12.1 (15.6 to 7.3)	0.001
Usual care	70.2 (11.5)	68.7 (10.4)	0.44	–	–		
Social functioning							
Exercise	79.1 (14.3)	87.7 (14.5)	0.001	85.5 (14.0)	0.001	8.6 (14.9 to 5.7)	0.002
Usual care	79.4 (14.5)	78.7 (12.4)	0.67	–	–		
Vitality							
Exercise	49.4 (9.3)	56.8 (9.5)	0.001	55.5 (9.0)	0.001	7.4 (12.9 to 4.3)	0.001
Usual care	49.2 (9.5)	48.7 (9.4)	0.63	–	–		
Physical component summary							
Exercise	66.1 (9.3)	72.7 (10.5)	0.003	72.0 (10.0)	0.001	6.6 (12.3 to 4.1)	0.001
Usual care	65.8 (9.0)	63.7 (9.4)	0.27	–	–		
Mental component summary							
Exercise	67.1 (11.0)	72.7 (12.1)	0.004	72.4 (12.4)	0.001	5.5 (9.6 to 3.3)	0.001
Usual care	69.2 (11.7)	68.7 (11.4)	0.56	–	–		
BFI							
Exercise	7.1 (2.0)	2.9 (1.5)	< 0.001	3.1 (1.9)	0.0001	−4.2 (−6.1 to −2.4)	< 0.001
Usual care	7.2 (2.1)	7.7 (2.4)	0.30	–	–		
CES-D							
Exercise	15.1 (3.3)	9.7 (2.5)	< 0.001	9.5 (3.0)	0.0001	6.6 (11.9 to 3.1)	< 0.001
Usual care	15.2 (3.5)	16.7 (3.4)	0.11	–	–		

**Abbreviations:** SD standard deviation, CI confidence interval; Short form-36 Health Status, *SF-36*; Brief Fatigue Index, *BFI*; Center for Epidemiological Studies Depression; *CES-D*

<sup>a</sup>P value for repeated measures ANOVA comparing changes in the exercise group from baseline to post-intervention, and in the usual care group from baseline to post-intervention

<sup>b</sup>P value for repeated measures ANOVA comparing changes in the exercise group from baseline to 3-month follow-up

<sup>c</sup>P value for mixed model analysis comparing changes between the exercise and usual care group from baseline to post-intervention



attributed to the deconditioned status of the participants enrolled within 6 months of the completion of cancer treatment. Our adherence of 96% exceeds the 70–80% noted in other trials [27–29], and could be attributed to flexible session timing (5 am – 8 pm, 7d/wk), one-on-one supervision, and the provision of parking permits or bus passes to overcome transportation barriers. Intentionally, we conducted the intervention in a controlled clinical setting under direct supervision to ensure exercise safety and dose intensity needed to elicit greater benefits in our outcomes.

Bone loss occurs as a consequence of breast cancer treatment [30]. Premenopausal breast cancer survivors may experience chemotherapy-induced amenorrhea or pharmacologic ovarian suppression treatment, predisposing them to further bone loss [30]. While we did not observe improvements in BMD, this may be explained by the short duration of our intervention. Interventions similar to ours that included aerobic and resistance exercise produced conflicting results and involved varying durations of exposure to exercise. Thomas et al. did not observe significant improvements in BMD following a 12-month aerobic and resistance exercise intervention in breast cancer survivors taking aromatase inhibitors (change from baseline: 0.001, 95% CI: -0.009, 0.010) [31]. Almstedt and Tarleton [32] observed improvements in T-scores at the femoral neck and whole body following 13 weeks of aerobic and resistance exercise + whole body vibration in female cancer survivors (breast cancer  $n = 5$ ). It is probable that the incorporation of whole body vibration contributed to the improvements BMD observed by Almstedt and Tarleton. Notably, we did observe a significant increase in osteocalcin and BSAP, a biomarkers of bone formation, so perhaps a longer intervention of a minimum of 6 months would elicit a positive effect on BMD.

Strengths of our study include the focus on high-risk breast cancer survivors with high rates of inactivity and obesity, targeting the early survivorship period, the ethnically-diverse sample, the randomized controlled trial design, the high adherence rate, and the modest loss-to-follow up. Limitations include lack of direct physical function and physical fitness measures (i.e., 1-RM and VO<sub>2</sub>max), and lack of an attention control group.

## Conclusions

In summary, a combined exercise intervention designed to improve metabolic syndrome in ethnically diverse, overweight or obese BCS also demonstrated significant improvements in patient-reported outcomes and physical fitness. Based on our findings, supervised clinical exercise programs that adhere to the ACS/ACSM exercise guidelines should be incorporated into breast cancer treatment and early survivorship care plans.

## Abbreviations

ACS: American Cancer Society; ACSM: American College of Sports Medicine; ANOVA: analysis of variance; BFI: Brief Fatigue Inventory; BMD: bone mineral density; BMI: body mass index; BSAP: bone-specific alkaline phosphatase; CES-D: Center for Epidemiologic Studies-Depression Scale; CTX: C-telopeptide of type 1 collagen; DXA: dual energy x-ray absorptiometry; FACT-B: Functional Assessment of Cancer Therapy-Breast; HR: heart rate; IRB: institutional review board; NTX: N-telopeptides of type 1 collagen; RANK: Receptor activator factor-kappa B; RANKL: Receptor activator factor-kappa B ligand; RM: repetition maximum; SD: standard deviation; SF-36: Short Form-36 Health Survey

## Acknowledgements

We acknowledge the Clinical Investigations Support Office of the Norris Comprehensive Cancer Center for their support of this investigation, the extraordinary generosity of our study participants- without their participation our study would not have been possible, and the exercise training staff for delivering an engaging and uniform intervention.

## Funding

This work was supported by grants K07CA160718 from the National Cancer Institute, UL1TR001855 and UL1TR000130 from the National Center for Advancing Translational Science (NCATS) of the U.S. National Institutes of Health.

## Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

## Authors' contributions

CMDC was responsible for conceptualization, funding acquisition, project administration, methodology, data curation, writing- original draft, review and editing. KSC was responsible for conceptualization, methodology, writing- original draft, review and editing. WDW was responsible for conceptualization, methodology, writing- original draft, review and editing. NS was responsible for project administration, methodology, data curation, writing- review and editing. KL was responsible for project administration, methodology, data curation, writing- review and editing. FCS was responsible for project administration, methodology, data curation, writing- review and editing. CS was responsible for project administration, methodology, data curation, writing- review and editing. TAB was responsible for conceptualization, methodology, writing- original draft, review and editing. DS was responsible for methodology, writing- original draft, review and editing. DT was responsible for methodology, writing- original draft, review and editing. LB was responsible for funding acquisition, methodology, writing- original draft, review and editing. JEM was responsible for conceptualization, funding acquisition, methodology, writing- original draft, review and editing. All authors read and approved the final manuscript.

## Ethics approval and consent to participate

The protocol and informed consent were approved (HS-12-00141) by the USC Institutional Review Board.

## Consent for publication

A signed informed consent was obtained from each participant. The informed consent is available upon request.

## Competing interests

The authors declare that they have no competing interests.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Author details

<sup>1</sup>Division of Biokinesiology and Physical Therapy, University of Southern California (USC), 11540 E. Alcazar St., CHP 155, Los Angeles, CA 90089, USA.

<sup>2</sup>Faculty of Kinesiology, Sport, and Recreation, University of Alberta,

Edmonton, AB T6G 2H9, Canada. <sup>3</sup>Department of Nutrition Sciences,

University of Alabama at Birmingham, Birmingham, AL 35294, USA. <sup>4</sup>Division

of Endocrinology and Diabetes, Keck School of Medicine, USC, Los Angeles, CA 90033, USA. <sup>5</sup>Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. <sup>6</sup>Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. <sup>7</sup>Division of Biomarkers of Early Detection and Prevention, Beckman Research Institute, City of Hope (COH), Duarte, CA 91010, USA. <sup>8</sup>Division of Medical Oncology and Experimental Therapeutics, COH, Duarte, CA 91010, USA.

Received: 26 July 2018 Accepted: 13 September 2018

Published online: 19 October 2018

## References

- Ording AG, Garne JP, Nystrom PM, Froslev T, Sorensen HT, Lash TL. Comorbid diseases interact with breast cancer to affect mortality in the first year after diagnosis—a Danish nationwide matched cohort study. *PLoS One*. 2013;8(10):e76013.
- Speck RM, Courneya KS, Masse LC, Duval S, Schmitz KH. An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. *J Cancer Surviv*. 2010;4(2):87–100.
- Dieli-Conwright CM, Courneya KS, Demark-Wahnefried W, Sami N, Lee K, Buchanan TA, et al. Effects of Aerobic and Resistance Exercise on Metabolic Syndrome, Sarcopenic Obesity, and Circulating Biomarkers in Overweight or Obese Survivors of Breast Cancer: A Randomized Controlled Trial. *J Clin Oncol*. 2018;36(9):875–83.
- Dieli-Conwright CM, Mortimer JE, Schroeder ET, Courneya K, Demark-Wahnefried W, Buchanan TA, et al. Randomized controlled trial to evaluate the effects of combined progressive exercise on metabolic syndrome in breast cancer survivors: rationale, design, and methods. *BMC Cancer*. 2014;14:238.
- Ebbling CB, Ward A, Puleo EM, Widrick J, Rippe JM. Development of a single-stage submaximal treadmill walking test. *Med Sci Sports Exerc*. 1991; 23(8):966–73.
- Brzycki M. Strength testing: Predicting a one-rep max from repetition-to-fatigue. *J Physic Educ Recreat Dance*. 1993;64:88–90.
- Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. *Cancer*. 1999;85(5):1186–96.
- Radloff LS. The CES-D Scale: A Self-Report Depression Scale for Research in the General Population. *Appl Psychol Meas*. 1977;1(3):385–401.
- Kriska AM, Knowler WC, LaPorte RE, Drash AL, Wing RR, Blair SN, et al. Development of questionnaire to examine relationship of physical activity and diabetes in Pima Indians. *Diabetes Care*. 1990;13(4):401–11.
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987;40(5):373–83.
- Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvao DA, Pinto BM, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. *Med Sci Sports Exerc*. 2010;42(7):1409–26.
- Ligibel JA, Campbell N, Partridge A, Chen WY, Salinardi T, Chen H, et al. Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. *J Clin Oncol*. 2008;26(6):907–12.
- Bower JE, Ganz PA, Desmond KA, Bernards C, Rowland JH, Meyerowitz BE, et al. Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. *Cancer*. 2006;106(4):751–8.
- Crosswell AD, Lockwood KG, Ganz PA, Bower JE. Low heart rate variability and cancer-related fatigue in breast cancer survivors. *Psychoneuroendocrinology*. 2014;45:58–66.
- Battaglini CL, Mills RC, Phillips BL, Lee JT, Story CE, Nascimento MG, et al. Twenty-five years of research on the effects of exercise training in breast cancer survivors: A systematic review of the literature. *World J Clin Oncol*. 2014;5(2):177–90.
- Mustian KM, Alfano CM, Heckler C, Kleckner AS, Kleckner IR, Leach CR, et al. Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis. *JAMA Oncol*. 2017;3(7):961–8.
- Patsou ED, Alexias GD, Anagnostopoulos FG, Karamouzis MV. Effects of physical activity on depressive symptoms during breast cancer survivorship: a meta-analysis of randomised control trials. *ESMO Open*. 2017;2(5):e000271.
- Dolan LB, Barry D, Petrella T, Davey L, Minnes A, Yantzi A, et al. The Cardiac Rehabilitation Model Improves Fitness, Quality of Life, and Depression in Breast Cancer Survivors. *J Cardiopulm Rehabil Prev*. 2017;38(4):246–252.
- Smith TM, Broomhall CN, Crecelius AR. Physical and Psychological Effects of a 12-Session Cancer Rehabilitation Exercise Program. *Clin J Oncol Nurs*. 2016;20(6):653–9.
- De Luca V, Minganti C, Borriore P, Grazioli E, Cerulli C, Guerra E, et al. Effects of concurrent aerobic and strength training on breast cancer survivors: a pilot study. *Public Health*. 2016;136:126–32.
- Campbell A, Mutrie N, White F, McGuire F, Kearney N. A pilot study of a supervised group exercise programme as a rehabilitation treatment for women with breast cancer receiving adjuvant treatment. *Eur J Oncol Nurs*. 2005;9(1):56–63.
- Milne HM, Wallman KE, Gordon S, Courneya KS. Effects of a combined aerobic and resistance exercise program in breast cancer survivors: a randomized controlled trial. *Breast Cancer Res Treat*. 2008;108(2):279–88.
- Mutrie N, Campbell AM, Whyte F, McConnachie A, Emslie C, Lee L, et al. Benefits of supervised group exercise programme for women being treated for early stage breast cancer: pragmatic randomised controlled trial. *BMJ*. 2007;334(7592):517.
- Brown JC, Harhay MO, Harhay MN. Physical function as a prognostic biomarker among cancer survivors. *Br J Cancer*. 2015;112(1):194–8.
- Sehl M, Lu X, Silliman R, Ganz PA. Decline in physical functioning in first 2 years after breast cancer diagnosis predicts 10-year survival in older women. *J Cancer Surviv*. 2013;7(1):20–31.
- Knobf MT, Jeon S, Smith B, Harris L, Thompson S, Stacy MR, et al. The Yale Fitness Intervention Trial in female cancer survivors: Cardiovascular and physiological outcomes. *Heart Lung*. 2017;46(5):375–81.
- Courneya KS, Segal RJ, Gelmon K, Reid RD, Mackey JR, Friedenreich CM, et al. Predictors of supervised exercise adherence during breast cancer chemotherapy. *Med Sci Sports Exerc*. 2008;40(6):1180–7.
- Arem H, Sorkin M, Cartmel B, Fiellin M, Capozza S, Harrigan M, et al. Exercise adherence in a randomized trial of exercise on aromatase inhibitor arthralgias in breast cancer survivors: the Hormones and Physical Exercise (HOPE) study. *J Cancer Surviv*. 2016;10(4):654–62.
- Schmitz KH, Ahmed RL, Hannan PJ, Yee D. Safety and efficacy of weight training in recent breast cancer survivors to alter body composition, insulin, and insulin-like growth factor axis proteins. *Cancer Epidemiol Biomark Prev*. 2005;14(7):1672–80.
- Santen RJ. Clinical review: Effect of endocrine therapies on bone in breast cancer patients. *J Clin Endocrinol Metab*. 2011;96(2):308–19.
- Thomas GA, Cartmel B, Harrigan M, Fiellin M, Capozza S, Zhou Y, et al. The effect of exercise on body composition and bone mineral density in breast cancer survivors taking aromatase inhibitors. *Obesity (Silver Spring)*. 2017; 25(2):346–51.
- Almstedt HC, Tarleton HP. Mind the gaps: missed opportunities to promote bone health among cancer survivors. *Support Care Cancer*. 2015;23(3):611–4.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

